Statistiche di base
| CIK | 1722271 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Akouos Inc
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| February 14, 2023 |
AKUS / Akouos Inc / Beryl Capital Management LLC Passive Investment SC 13G/A 1 akus13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Akouos, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 00973J101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 10, 2023 |
AKUS / Akouos Inc / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 akus13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Akouos, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973J101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| January 10, 2023 |
AKUS / Akouos Inc / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 form772.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3*) AKOUOS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 00973J101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39343 AKOUOS, INC. (Exact name of registrant as specified in its charter |
|
| December 2, 2022 |
AKUS / Akouos Inc / 5AM Ventures V, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Akouos, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00973J101 (CUSIP Number) 5AM Venture Management, LLC 501 2nd Street, Suite 350 |
|
| December 1, 2022 |
Amended and Restated Certificate of Incorporation of Akouos, Inc. EX-3.1 Exhibit 3.1 Amended and Restated Certificate of Incorporation of Akouos, Inc. 1. The name of the corporation formed hereby is Akouos, Inc. (the “Corporation”). 2. The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street, Wilmington, New Castle County, Delaware 19801, and the name of the Corporation’s registered agent at such address is National Regis |
|
| December 1, 2022 |
Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases EX-2.6 Exhibit 2.6 Dec. 1, 2022 For Release: Dec. 1, 2022 @ 8:41 a.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases INDIANAPOLIS, Dec. 1, 2022 — Eli Lilly and Company (NYSE: LLY) today announced the successful completio |
|
| December 1, 2022 |
Amended and Restated Bylaws of Akouos, Inc. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF AKOUOS, INC. (a Delaware corporation) ARTICLE I STOCKHOLDERS Section 1. Annual Meetings. The annual meeting of the stockholders of Akouos, Inc. (the “Corporation”) for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held each year at such date and time, within or without the |
|
| December 1, 2022 |
As filed with the Securities and Exchange Commission on December 1, 2022 S-8 POS 1 d405746ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on December 1, 2022 Registration No. 333-239571 Registration No. 333-254803 Registration No. 333-263938 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-239571 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATIO |
|
| December 1, 2022 |
As filed with the Securities and Exchange Commission on December 1, 2022 As filed with the Securities and Exchange Commission on December 1, 2022 Registration No. |
|
| December 1, 2022 |
As filed with the Securities and Exchange Commission on December 1, 2022 As filed with the Securities and Exchange Commission on December 1, 2022 Registration No. |
|
| December 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 30, 2022 Akouos, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39343 81-1716654 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 1, 2022 |
AKUS / Akouos Inc / ELI LILLY & Co - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* Under the Securities Exchange Act of 1934 Akouos, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 00973J101 (CUSIP Number) Anat Hakim Executive Vice President, General Counsel and Secretary Eli Lilly and Company Lilly Corporate Center India |
|
| December 1, 2022 |
As filed with the Securities and Exchange Commission on December 1, 2022 As filed with the Securities and Exchange Commission on December 1, 2022 Registration No. |
|
| November 30, 2022 |
Joint Press Release issued on November 30, 2022. Exhibit (a)(5)(B) Nov. 30, 2022 For Release: Nov. 30, 2022 @ 6:50 a.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Lilly Media) Joe Fletcher; [email protected]; 317-296-2884 (Lilly Investors) Lee-Ann Murphy; [email protected] (Akouos Media) Courtney Turiano; [email protected] (Akouos Investors) Lilly and Akouos Announce Expiration of Akouos Tender Offer INDIANA |
|
| November 30, 2022 |
SC 14D9/A 1 d414817dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 AKOUOS, INC. (Name of Subject Company) AKOUOS, INC. (Name of Persons Filing Statement) Common stock, par value $0.0001 per share (Title of Class of Secur |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) AKOUOS, INC. (Name of Subject Company (issuer)) KEARNY ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifying sta |
|
| November 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 AKOUOS, INC. (Name of Subject Company) AKOUOS, INC. (Name of Persons Filing Statement) Common stock, par value $0.0001 per share (Title of Class of Securities) 00973J 101 (CUSIP Number of Class o |
|
| November 28, 2022 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) AKOUOS, INC. (Name of Subject Company (issuer)) KEARNY ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (ident |
|
| November 18, 2022 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 AKOUOS, INC. (Name of Subject Company) AKOUOS, INC. (Name of Persons Filing Statement) Common stock, par value $0.0001 per share (Title of Class of Securities) 00973J 101 (CUSIP Number |
|
| November 14, 2022 |
Condensed Consolidated Balance Sheet Data (in thousands) Exhibit 99.1 ? Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights -Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial ? -Continued progress toward planned IND submission for AK-antiVEGF in 2023 ? -Announced on October 18 definitive agreement for Eli Lilly and Company to acquire Akouos ? BOS |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 AKOUOS, INC. (Name of Subject Company) AKOUOS, INC. (Name of Persons Filing Statement) Common stock, par value $0.0001 per share (Title of Class of Securities) 00973J 101 (CUSIP Number of Class o |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) AKOUOS, INC. (Name of Subject Company (issuer)) KEARNY ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifying sta |
|
| November 14, 2022 |
Consulting Agreement, dated August 15, 2022, by and between the registrant and Chris Smith Exhibit 10.1 CONSULTING AGREEMENT ? THIS CONSULTING AGREEMENT (the ?Agreement?) is entered into and effective as of August 15, 2022 (the ?Effective Date?), by and between Akouos, Inc. (?Akouos?), a Delaware corporation, with an office located at 645 Summer Street, Suite 200, Boston, MA 02210, and Chris Smith (?Consultant.) ? 1.Description of Services. Consultant is hereby retained by Akouos to per |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of report (Date of earliest event reported): November 14, 2022 ? Akouos, Inc. (Exact name of registrant as specified in its charter) ? Delaware 001-39343 81-1716654 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 31, 2022 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of AKOUOS, INC. |
|
| October 31, 2022 |
AKOUOS, INC. Notice to Equity Award Holders October 31, 2022 Exhibit (a)(1)(F) AKOUOS, INC. Notice to Equity Award Holders October 31, 2022 Dear Akouos Equity Award Holder: On October 17, 2022, Akouos, Inc. (the ?Company?) entered into an Agreement and Plan of Merger with Eli Lilly and Company (?Lilly?) and Lilly?s wholly-owned subsidiary, Kearny Acquisition Corporation (the ?Purchaser?), pursuant to which Purchaser will commence a tender offer (the ?Offer? |
|
| October 31, 2022 |
Form of Letter of Transmittal (including Internal Revenue Service Form W-9). Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of AKOUOS, INC. |
|
| October 31, 2022 |
Exhibit (d)(6) Execution Version JUNE 16, 2022 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 Attention: Kenneth L. |
|
| October 31, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 AKOUOS, INC. (Name of Subject Company) AKOUOS, INC. (Name of Persons Filing Statement) Common stock, par value $0.0001 per share (Title of Class of Securities) 00973J 101 (CUSIP Number of Class o |
|
| October 31, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO AKOUOS, INC. (Name of Subject Company (issuer)) KEARNY ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifying status as offeror, issuer or other person)) Table 1-Transaction Valuation Transaction Valuation* Fee rate Amount of Filing Fee** Fees to Be Paid |
|
| October 31, 2022 |
Summary Advertisement, as published in The Wall Street Journal on October 31, 2022. Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| October 31, 2022 |
Offer to Purchase, dated October 31, 2022. Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of AKOUOS, INC. |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 AKOUOS, INC. (Name of Subject Company (issuer)) KEARNY ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifying status as offeror, is |
|
| October 31, 2022 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of AKOUOS, INC. |
|
| October 28, 2022 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Akouos, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00973J101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, |
|
| October 28, 2022 |
AKUS / Akouos Inc / Beryl Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Akouos, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 00973J101 (CUSIP Number) October 18, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| October 27, 2022 |
AKUS / Akouos Inc / ELI LILLY & Co - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 AKOUOS, INC. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 00973J101 (CUSIP Number) Anat Hakim Executive Vice President, General Counsel and Secretary Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 Telep |
|
| October 27, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement is being jointly filed, and all amendments thereto will be jointly filed, by Eli Lilly and Company, as the main and designated filer, on behalf of each of the persons and entities named below that is named as a r |
|
| October 18, 2022 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among ELI LILLY AND COMPANY, KEARNY ACQUISITION CORPORATION and AKOUOS, INC. Dated as of October 17, 2022 TABLE OF CONTENTS Page Article I THE OFFER 6 Section 1.1. The Offer 6 Section 1.2. Company Consent; Schedule 14D-9 9 Section 1.3. Stockholder Lists 10 Article II THE MERGER 10 Section 2.1. The Merger 10 Section 2.2. Closing; Effective |
|
| October 18, 2022 |
Exhibit 99.2 Email from Manny Simons to Akouos Employees Subject: Today?s exciting news! Team, I am excited to share that today Akouos and Lilly announced an agreement for Akouos to be acquired by Lilly, where we will bring our first-in-class gene therapy programs with the potential to treat inner ear conditions to the Lilly Institute for Genetic Medicine. The full press release with additional de |
|
| October 18, 2022 |
Exhibit 99.5: Email to clinical trial investigators, dated October 18, 2022. Exhibit 99.5 Email to Clinical Trial Investigators Subject: Exciting news from Akouos Hi [INSERT NAME], Today Akouos and Lilly announced an agreement for Akouos to be acquired by Lilly, where we will bring our first-in-class gene therapy programs with the potential to treat inner ear conditions to the Lilly Institute for Genetic Medicine. The full press release with additional details can be found |
|
| October 18, 2022 |
Exhibit 2.4 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of October 17, 2022, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Kearny Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent (“Purchaser”), and one or more stockholders of Akouos, Inc., a Delaw |
|
| October 18, 2022 |
Exhibit 2.5 Final Form FORM OF CONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [●] (this “Agreement”), is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Kearny Acquisition Corp., a Delaware corporation and wholly owned Subsidiary of Parent (“Purchaser”), and [●], a [●], as Rights Agent (as defined herein). Capitalized terms |
|
| October 18, 2022 |
Exhibit 99.1 October 18, 2022 For Release: Immediately Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Lilly Media) Joe Fletcher; [email protected]; 317-296-2884 (Lilly Investors) Lee-Ann Murphy; [email protected] (Akouos Media) Courtney Turiano; [email protected] (Akouos Investors) Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss Proposed a |
|
| October 18, 2022 |
EX-99.1 Exhibit 99.1 October 18, 2022 For Release: Immediately Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Lilly Media) Joe Fletcher; [email protected]; 317-296-2884 (Lilly Investors) Lee-Ann Murphy; [email protected] (Akouos Media) Courtney Turiano; [email protected] (Akouos Investors) Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss Pr |
|
| October 18, 2022 |
Exhibit 2.2 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of October 17, 2022, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Kearny Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent (“Purchaser”), and one or more stockholders of Akouos, Inc., a Delaware co |
|
| October 18, 2022 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 AKOUOS, INC. (Name of Subject Company (issuer)) KEARNY ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifying status as off |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 17, 2022 Akouos, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39343 81-1716654 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| October 18, 2022 |
Exhibit 99.3: Email to partners, dated October 18, 2022. Exhibit 99.3 Email to Key Partners Subject: Exciting news from Akouos Hi [INSERT NAME], Today Akouos and Lilly announced an agreement for Akouos to be acquired by Lilly, where we will bring our first-in-class gene therapy programs with the potential to treat inner ear conditions to the Lilly Institute for Genetic Medicine. The full press release with additional details can be found here [INSERT LI |
|
| October 18, 2022 |
Exhibit 99.4: Email to advocacy groups, dated October 18, 2022. Exhibit 99.4 Email to Advocacy Organizations Subject: Exciting news from Akouos Hi [INSERT NAME], Today Akouos and Lilly announced an agreement for Akouos to be acquired by Lilly, where we will bring our first-in-class gene therapy programs with the potential to treat inner ear conditions to the Lilly Institute for Genetic Medicine. The full press release with additional details can be found here |
|
| October 18, 2022 |
Exhibit 2.3 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of October 17, 2022, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Kearny Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent (“Purchaser”), and one or more stockholders of Akouos, Inc., a Delaware co |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 AKOUOS, INC. (Name of Subject Company) AKOUOS, INC. (Name of Person(s) Filing Statement) Common stock, par value $0.0001 per share (Title of Class of Securities) 00973J101 (CUSIP Number of Class of Securities) Emm |
|
| September 9, 2022 |
AKUS / Akouos Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2*) AKOUOS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 00973J101 (CUSIP Number) August 31, 2022 (Date of Event Which Requires Filing of this Statement) |
|
| August 25, 2022 |
SC 13G/A (Amendment No. 2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Akouos, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973J101 (CUSIP Number) August 25, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 15, 2022 Akouos, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39343 81-1716654 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 15, 2022 |
Condensed Consolidated Balance Sheet Data (in thousands) Exhibit 99.1 ? Akouos Reports Second Quarter 2022 Financial Results and Provides Business Highlights - Submitted IND for AK-OTOF to FDA ? - Continued progress toward planned IND submission for AK-antiVEGF ? - Presented new nonclinical data at ASGCT supporting the proposed clinical development of AK-OTOF and highlighting strategies for regulated gene expression in the inner ear ? - Received a notic |
|
| August 15, 2022 |
AKUS / Akouos Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* AKOUOS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973J101 (CUSIP Number) August 15, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| July 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 21, 2022 Akouos, Inc. (Exact name of registrant as specified in its charter) ? Delaware 001-39343 81-1716654 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 27, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 23, 2022 Akouos, Inc. (Exact name of registrant as specified in its charter) ? Delaware 001-39343 81-1716654 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 23, 2022 |
AKUS / Akouos Inc / Venrock Healthcare Capital Partners II, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Akouos, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973J101 (CUSIP Number) May 12, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant t |
|
| May 12, 2022 |
Summary of Amended and Restated Non-employee Director Compensation Program Exhibit 10.1 AKOUOS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Effective as of January 1, 2022, the non-employee directors of Akouos, Inc. (the ?Company?) shall receive the following compensation for their service as members of the Board of Directors (the ?Board?) of the Company. Director Compensation Our goal is to provide compensation for our non-employee directors in a |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 12, 2022 |
Condensed Consolidated Balance Sheet Data (in thousands) Exhibit 99.1 ? Akouos Reports First Quarter 2022 Financial Results and Provides Business Highlights - Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 ? - Presenting new nonclinical data at ASGCT supporting the planned clinical development of AK-OTOF and highlighting the potential use of microRNA target sites in AAV vectors for regulat |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of report (Date of earliest event reported): May 12, 2022 ? Akouos, Inc. (Exact name of registrant as specified in its charter) ? Delaware 001-39343 81-1716654 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 28, 2022 |
TABLE OF CONTENTS ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 29, 2022 |
As filed with the Securities and Exchange Commission on March 29, 2022 As filed with the Securities and Exchange Commission on March 29, 2022 Registration No. |
|
| March 29, 2022 |
? Exhibit 107 Calculation of Filing Fee Table ? Form S-8 (Form Type) Akouos, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1?Newly Registered Securities ? ? ? ? ? ? ? ? ? Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, |
|
| March 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of report (Date of earliest event reported): March 29, 2022 ? Akouos, Inc. (Exact name of registrant as specified in its charter) ? Delaware 001-39343 81-1716654 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 29, 2022 |
Condensed Consolidated Balance Sheet Data (in thousands) Exhibit 99.1 ? Akouos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights - Advanced toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 ? - Presented data at ARO demonstrating potential of precision genetic medicine platform to address a broad range of inner ear conditions ? - Expanded leadership team with appointme |
|
| February 14, 2022 |
AKUS / Akouos Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1*) AKOUOS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 00973J101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statemen |
|
| February 14, 2022 |
AKUS / Akouos Inc / Pivotal bioVenture Partners Fund I, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Akouos, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973J101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 14, 2022 |
AKUS / Akouos Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* AKOUOS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973J101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 14, 2022 |
EX-99.1 2 d237570dex991.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(l)(iii) under the Securities Exchange Act of 1934. Date: February 14, |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 12, 2021 |
Condensed Consolidated Balance Sheet Data (in thousands) EX-99.1 2 akus-20211112xex99d1.htm EX-99.1 Exhibit 99.1 Akouos Reports Third Quarter 2021 Financial Results and Provides Business Highlights - Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Expanded leadership team with appointment of Stacy Price as chief technical officer BOSTON, November 12, 2021 – Akouos, Inc. (Nasdaq: AKUS), a |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 12, 2021 Akouos, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39343 81-1716654 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 26, 2021 |
TABLE OF CONTENTS ? Filed Pursuant to Rule 424(b)(3) ?Registration No. 333-258798? PROSPECTUS $100,000,000 Common Stock ? We have entered into a sales agreement, or the sales agreement, with Cowen and Company, LLC, or Cowen, relating to the sale of shares of our common stock, par value $0.0001 per share, offered by this prospectus. In accordance with the terms of the sales agreement, under this pr |
|
| August 18, 2021 |
AKOUOS, INC. 645 Summer Street, Suite 200 Boston, MA 02210 AKOUOS, INC. 645 Summer Street, Suite 200 Boston, MA 02210 August 18, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Akouos, Inc. Registration Statement on Form S-3 File No. 333-258798 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Akouos, |
|
| August 13, 2021 |
Exhibit 4.4 AKOUOS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inapplicable 314 |
|
| August 13, 2021 |
Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| August 13, 2021 |
Form of Subordinated Indenture Exhibit 4.5 AKOUOS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inapplica |
|
| August 13, 2021 |
As filed with the Securities and Exchange Commission on August 13, 2021 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 13, 2021 Registration No. |
|
| August 13, 2021 |
Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| August 13, 2021 |
Exhibit 1.2 AKOUOS, INC. $100,000,000 COMMON STOCK SALES AGREEMENT August 13, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Akouos, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1.??????????????? Issuance and Sale of Shares. The Company agrees that, from time to |
|
| August 12, 2021 |
Employment Agreement by and between the registrant and Jennifer Wellman, dated as of August 12, 2021 ? Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), is made and entered into by and between Akouos, Inc. (the ?Company?), and Jennifer Wellman (?Executive?), and is effective as of August 12, 2021 (the ?Effective Date?). RECITALS Whereas, the Company desires to continue to employ Executive as its Chief Operating Officer; and Whereas, Executive is party to a letter agre |
|
| August 12, 2021 |
Employment Agreement by and between the registrant and Michael McKenna, dated as of August 12, 2021 ? Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), is made and entered into by and between Akouos, Inc. (the ?Company?), and Michael McKenna (?Executive?), and is effective as of August 12, 2021 (the ?Effective Date?). RECITALS Whereas, the Company desires to continue to employ Executive as its Chief Medical Officer; and Whereas, Executive is party to a letter agreeme |
|
| August 12, 2021 |
Employment Agreement by and between the registrant and Greg Robinson, dated as of August 12, 2021 ? Exhibit 10.4 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), is made and entered into by and between Akouos, Inc. (the ?Company?), and Greg Robinson (?Executive?), and is effective as of August 12, 2021 (the ?Effective Date?). RECITALS Whereas, the Company desires to continue to employ Executive as its Chief Scientific Officer; and Whereas, Executive is party to a letter agreem |
|
| August 12, 2021 |
Condensed Consolidated Balance Sheet Data (in thousands) EX-99.1 2 akus-20210812xex99d1.htm EX-99.1 Exhibit 99.1 Akouos Reports Second Quarter 2021 Financial Results and Provides Business Highlights - Announced European Commission designation of AK-OTOF as an orphan drug for the treatment of otoferlin gene-mediated hearing loss - Advanced both AK-OTOF and AK-antiVEGF towards planned IND submissions in the first half of 2022 and in 2022, respectively - C |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 12, 2021 |
? Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), is made and entered into by and between Akouos, Inc. (the ?Company?), and Sachiyo Minegishi (?Executive?), and is effective as of August 12, 2021 (the ?Effective Date?). RECITALS Whereas, the Company desires to continue to employ Executive as its Chief Financial Officer; and Whereas, Executive is party to a letter agr |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of report (Date of earliest event reported): August 12, 2021 ? Akouos, Inc. (Exact name of registrant as specified in its charter) ? Delaware 001-39343 81- 1716654 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 25, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 24, 2021 Akouos, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39343 81- 1716654 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 13, 2021 |
Condensed Consolidated Balance Sheet Data (in thousands) Exhibit 99.1 Akouos Reports First Quarter 2021 Financial Results and Provides Business Updates - Leadership team expanded with appointment of Kathy Reape, M.D. as chief development officer - AK-OTOF granted both Orphan Drug Designation and Rare Pediatric Disease Designation by FDA and is on track for planned IND submission in first half of 2022 - Nonclinical data supporting future clinical develop |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of report (Date of earliest event reported): May 13, 2021 ? Akouos, Inc. (Exact name of registrant as specified in its charter) ? Delaware 001-39343 81- 1716654 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 13, 2021 |
EX-10.1 2 akus-20210331ex101d0444e.htm EX-10.1 Exhibit 10.1 645 SUMMER STREET Boston, MA First Amendment to Lease Akouos, Inc. THIS FIRST AMENDMENT TO LEASE (“First Amendment”) is made as of January 29, 2021 (the “Effective Date”) by and between OPG mp parcel owner (de) llc, a Delaware limited liability company, as successor in interest to Boston Harbor Industrial Development LLC (“Landlord”), and |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 28, 2021 |
definitive proxy statement for the 2021 Annual Meeting of Stockholders; Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 28, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| March 29, 2021 |
As filed with the Securities and Exchange Commission on March 29, 2021 Registration No. |
|
| March 29, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 29, 2021 |
Separation Agreement, dated November 19, 2020, by and between the registrant and Rabia Gurses Ozden EX-10.18 3 akus-20201231ex1018c8092.htm EX-10.18 Exhibit 10.18 VIA ELECTRONIC MAIL November 19, 2020 Dr. Rabia Gurses Ozden Dear Rabia: This letter agreement confirms our agreement with respect to your separation from employment with Akouos, Inc. (the “Company”). As we have discussed, provided that you timely sign and return this letter agreement, the Company will continue to employ you through a |
|
| March 29, 2021 |
Condensed Consolidated Balance Sheet Data (in thousands) EX-99.1 2 tmb-20210329xex99d1.htm EX-99.1 Exhibit 99.1 Akouos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights - In 2020, continued to advance genetic medicine pipeline with execution of IND-enabling studies for AK-OTOF and general alignment with FDA on the path to a 2022 IND submission for AK-antiVEGF - Raised approximately $349 million in gross proceed |
|
| March 29, 2021 |
EX-4.3 2 akus-20201231ex4332cc11a.htm EX-4.3 Exhibit 4.3 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of the securities of Akouos, Inc. (“us,” “our,” “we” or the “Company”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is intended as a summary only and theref |
|
| March 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of report (Date of earliest event reported): March 29, 2021 ? Akouos, Inc. (Exact name of registrant as specified in its charter) ? Delaware 001-39343 81- 1716654 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AKOUOS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973J101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Akouos, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973J101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 12, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. *) AKOUOS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 00973J101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement |
|
| February 9, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Akouos, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00973J101 (CUSIP Number) December 31, 2020 (Date of Event Wh |
|
| February 4, 2021 |
Entry into a Material Definitive Agreement - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 29, 2021 Akouos, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39343 81- 1716654 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Akouos, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00973J101 (CUSIP Number) 5AM Venture Management, LLC 501 2nd Street, Suite 350 |
|
| December 1, 2020 |
Exhibit 99.1 December 2020 This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, including, but not limited to: our expectation about timing and execution of anticipated milestones, including our planned IND submissions and initiation of clinical trials; our expectatio |
|
| December 1, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 1, 2020 Akouos, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39343 81- 1716654 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 12, 2020 |
Exhibit 99.1 Akouos Reports Third Quarter 2020 Financial Results and Provides Business Highlights - Expanded leadership team with appointment of Sachiyo Minegishi as CFO and promotion of Jennifer Wellman to COO - - Continued progress towards 2021 IND submission for AK-OTOF, a gene therapy intended for the treatment of hearing loss due to mutations in the OTOF gene - - Execution on build of interna |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 12, 2020 Akouos, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39343 81- 1716654 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3934 |
|
| October 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 1, 2020 Akouos, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39343 81- 1716654 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 13, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39343 AKO |
|
| August 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 13, 2020 Akouos, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39343 81- 1716654 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 13, 2020 |
Exhibit 99.1 Akouos Reports Second Quarter 2020 Financial Results and Provides Business Highlights - Upsized IPO in June 2020 raised $244.4 million in gross proceeds - - Company plans to advance lead product candidate, AK-OTOF, for the treatment of hearing loss due to mutations in the OTOF gene, to IND submission in 2021 and advance development programs spanning multiple inner ear disorders - BOST |
|
| July 10, 2020 |
CABA / Cabaletta Bio, Inc. / 5am Ventures V, L.p. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Akouos, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00973J101 (CUSIP Number) 5AM Venture Management, LLC 501 2nd Street, Suite 350 S |
|
| July 10, 2020 |
Exhibit 1 Exhibit 1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. |
|
| July 10, 2020 |
AKUS / Akouos, Inc. / Pivotal Bioventure Partners Fund I, L.p. - SCHEDULE 13D Activist Investment Schedule 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Akouos, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00973J101 (CUSIP Number) Heather Preston Pivotal bioVenture Partners Fund I U.G.P. 501 2nd Street, Suite 200 San Francisco, CA 94107 (415) 697-1002 (Name, Address and |
|
| July 7, 2020 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Akouos, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00973J101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, |
|
| June 30, 2020 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF AKOUOS, INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Record Date for Stockholder Meetings 2 1.5 Notice of Meetings 2 1.6 Voting List 3 1.7 Quorum 3 1.8 Adjournments 4 1.9 Voting and Proxies 4 1.10 Action at Meeting 4 1.11 Nomination of Directors 4 1.12 Notice of Business at An |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2020 Akouos, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39343 81- 1716654 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| June 30, 2020 |
Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF AKOUOS, INC. Akouos, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify that the name of the corporation is Akouos, Inc. and the original certificate of incorporation of the corporation was filed with the Secretary of State of the State of Delaware on November 23, 2016. This |
|
| June 30, 2020 |
As filed with the Securities and Exchange Commission on June 30, 2020 Registration No. |
|
| June 26, 2020 |
12,500,000 Shares Common Stock Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. |
|
| June 25, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on June 25, 2020 Registration No. |
|
| June 23, 2020 |
June 23, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 23, 2020 |
June 23, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 22, 2020 |
Exhibit 10.11 Akouos, Inc. 2020 EMPLOYEE STOCK PURCHASE PLAN The purpose of this 2020 Employee Stock Purchase Plan (this “Plan”) is to provide eligible employees of Akouos, Inc. (the “Company”) and certain of its subsidiaries with opportunities to purchase shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), commencing at such time and on such dates as the Board |
|
| June 22, 2020 |
Form 8-A as filed with the SEC on June 22, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Akouos, Inc. (Exact name of registrant as specified in its charter) Delaware 81-1716654 (State of incorporation or organization) (I.R.S. Employer Identification No.) 645 Summer Street Suite 200 Bos |
|
| June 22, 2020 |
Exhibit 10.7 Akouos, Inc. 2020 STOCK PLAN 1. Purpose The purpose of this 2020 Stock Plan (the “Plan”) of Akouos, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ow |
|
| June 22, 2020 |
June 22, 2020 By Electronic Submission Rosemary G. Reilly +1 617 526 6633 (t) +1 617 526 5000 (f) [email protected] Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Chris Edwards Re: Akouos, Inc. Registration Statement Filed June 5, 2020 File No. 333-238977 Ladies and Gentlemen: On behalf of Akouos, Inc. (the “Compan |
|
| June 22, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on June 22, 2020 Registration No. |
|
| June 22, 2020 |
Exhibit 3.5 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AKOUOS, INC. Akouos, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: A resolution was duly adopted by the Board of Directors of the Corporation pur |
|
| June 22, 2020 |
Form of Underwriting Agreement Exhibit 1.1 AKOUOS, INC. (a Delaware corporation) [·] Shares of Common Stock UNDERWRITING AGREEMENT Dated: [·], 2020 AKOUOS, INC. (a Delaware corporation) [·] Shares of Common Stock UNDERWRITING AGREEMENT [·], 2020 BofA Securities, Inc. Cowen and Company, LLC Piper Sandler & Co. as Representatives of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o Co |
|
| June 11, 2020 |
+1 617 526 6000 (t) +1 617 526 5000 (f) FOIA CONFIDENTIAL TREATMENT REQUEST The entity requesting confidential treatment is: Akouos, Inc. |
|
| June 5, 2020 |
Exhibit 3.3 RESTATED CERTIFICATE OF INCORPORATION OF AKOUOS, INC. Akouos, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify that the name of the corporation is Akouos, Inc. and the original certificate of incorporation of the corporation was filed with the Secretary of State of the State of Delaware on November 23, 2016. This |
|
| June 5, 2020 |
Exhibit 10.16 Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. EXECUTION VERSION AKOUOS, INC. [**] October 27, 2017 Massachusetts Eye and Ear Infirmary John Fernandez, President and CEO 243 Charles St. Boston, MA 02114 The Schepens |
|
| June 5, 2020 |
Exhibit 10.12 LEASE BETWEEN BOSTON HARBOR INDUSTRIAL DEVELOPMENT LLC AND AKOUOS, INC. ARTICLE 1 Reference Data 1.1 Introduction: Each reference in this Lease to any of the following subjects shall be construed to incorporate the data stated for that subject in this Section 1.1. Lease Date: As of Dec. 28, 2018 Building: The building located at 645 Summer Street, Boston, MA, containing approximately |
|
| June 5, 2020 |
Form of Stock Grant Agreement (for Services) under 2016 Stock Plan Exhibit 10.6 AKOUOS, INC. 2016 STOCK PLAN: SUMMARY OF STOCK GRANT (FOR SERVICES) The Transferee is acquiring shares of the Common Stock of Akouos, Inc. on the following terms: Name of Transferee: «Name» Total Number of Transferred Shares: «TotalShares» Date of Transfer: «DateTransfer» Vesting Commencement Date: «VestComDate» Vesting Schedule: The Forfeiture Condition shall lapse with respect to th |
|
| June 5, 2020 |
Exhibit 4.2 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 27th day of February, 2020, by and among Akouos, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, along with any additional investo |
|
| June 5, 2020 |
Form of Stock Option Agreement (Fully Vested) under 2016 Stock Plan Exhibit 10.3 AKOUOS, INC. 2016 STOCK PLAN NOTICE OF STOCK OPTION GRANT (FULLY VESTED) The Optionee has been granted the following option to purchase shares of the Common Stock of Akouos, Inc.: Name of Optionee: «Name» Total Number of Shares: «TotalShares» Type of Option: «ISO» Incentive Stock Option (ISO) «NSO» Nonstatutory Stock Option (NSO) Exercise Price per Share: $«PricePerShare» Date of Gran |
|
| June 5, 2020 |
Form of Stock Option Agreement (Early Exercise) under 2016 Stock Plan Exhibit 10.2 AKOUOS, INC. 2016 STOCK PLAN NOTICE OF STOCK OPTION GRANT (EARLY EXERCISE) The Optionee has been granted the following option to purchase shares of the Common Stock of Akouos, Inc.: Name of Optionee: «Name» Total Number of Shares: «TotalShares» Type of Option: «ISO» Incentive Stock Option (ISO) «NSO» Nonstatutory Stock Option (NSO) Exercise Price per Share: $«PricePerShare» Date of Gr |
|
| June 5, 2020 |
Exhibit 10.1 AKOUOS, INC. 2016 STOCK PLAN ADOPTED ON MARCH 1, 2017 TABLE OF CONTENTS Page SECTION 1. ESTABLISHMENT AND PURPOSE 1 SECTION 2. ADMINISTRATION 1 (a) Committees of the Board of Directors 1 (b) Authority of the Board of Directors 1 SECTION 3. ELIGIBILITY 1 (a) General Rule 1 (b) Ten-Percent Stockholders 1 SECTION 4. STOCK SUBJECT TO PLAN 2 (a) Basic Limitation 2 (b) Additional Shares 2 S |
|
| June 5, 2020 |
Form of Stock Purchase Agreement under 2016 Stock Plan Exhibit 10.5 AKOUOS, INC. 2016 STOCK PLAN: SUMMARY OF STOCK PURCHASE The Purchaser is acquiring shares of the Common Stock of Akouos, Inc. on the following terms: Name of Purchaser: Total Number of Purchased Shares: Purchase Price per Share: Date of Purchase: Vesting Commencement Date: Vesting Schedule: By signing below, the Purchaser and the Company agree that the acquisition of the Purchased Sha |
|
| June 5, 2020 |
Exhibit 3.2 BYLAWS OF AKOUOS, INC. ARTICLE I OFFICES 1.1 Registered Office. The registered office shall be in the City of Wilmington, County of New Castle, State of Delaware. 1.2 Offices. The corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directors may from time to time determine or the business of the corporation may require. A |
|
| June 5, 2020 |
Form of Restricted Stock Unit Agreement under 2020 Stock Plan Exhibit 10.10 Akouos, Inc. RESTRICTED STOCK UNIT AGREEMENT Akouos, Inc. (the “Company”) hereby grants the following restricted stock units pursuant to its 2020 Stock Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number of restricted stock units (“RSUs”) granted: Vesting Start Date: Vesting Schedule: Vesting |
|
| June 5, 2020 |
Exhibit 10.14 EXECUTION VERSION Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. LICENSE AGREEMENT between MASSACHUSETTS EYE AND EAR INFIRMARY AND THE SCHEPENS EYE RESEARCH INSTITUTE, INC. and AKOUOS, INC. TABLE OF CONTENTS Page Art |
|
| June 5, 2020 |
Letter Agreement, dated June 3, 2020, by and between the registrant and Emmanuel Simons Exhibit 10.17 Our Mission: Healthy hearing available to all. June 3, 2020 Emmanuel Simons c/o Akouos, Inc. 645 Summer Street Suite 200 Boston, MA 02210 Dear Manny: On behalf of Akouos, Inc. (the “Company”), I am pleased to set forth below the terms of your continued employment with the Company, which will take effect as of the closing of the Company’s initial public offering of its common stock (t |
|
| June 5, 2020 |
Exhibit 10.15 EXECUTION VERSION Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. SUBLICENSE AGREEMENT between LONZA HOUSTON, INC. and AKOUOS, INC. TABLE OF CONTENTS Page Article 1 - Definitions 1 Article 2 - Grant of Licenses, Reser |
|
| June 5, 2020 |
Form of Stock Option Agreement under 2020 Stock Plan Exhibit 10.8 Akouos, Inc. STOCK OPTION AGREEMENT Akouos, Inc. (the “Company”) hereby grants the following stock option pursuant to its 2020 Stock Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Incentive Stock Option or Nonstatutory Stock Option: Number of shares of the Company’s Common Stock subject to this o |
|
| June 5, 2020 |
Form of Bylaws of the registrant (to be effective upon the closing of this offering) Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF AKOUOS, INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Record Date for Stockholder Meetings 1 1.5 Notice of Meetings 2 1.6 Voting List 2 1.7 Quorum 3 1.8 Adjournments 3 1.9 Voting and Proxies 4 1.10 Action at Meeting 4 1.11 Nomination of Directors 5 1.12 Notice of Business at An |
|
| June 5, 2020 |
Exhibit 10.13 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [ ], 20[ ] by and between Akouos, Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”) [[Solely with respect to officers and directors that execute this form of indemnification agreement on or prior to the Company’s initial public offering:] and shall be effective as of the effectiven |
|
| June 5, 2020 |
Specimen Stock Certificate evidencing the shares of common stock Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# . COMMON STOCK PAR VALUE $0.0001 COMMON STOCK Certificate Number ZQ00000000 Shares * * 0 0 0 0 0 0 * * * * * * * * * * * * * * * * * * * * * 0 0 0 0 0 0 * * * * * * * * * * * * * * * * * * * * * 0 0 0 0 0 0 * * * * * * * * * * * * * * * * * * * * * 0 0 0 0 0 0 * * * * * * * * * * * * * * * * * * * * * 0 0 0 0 0 0 * * * * * * * * * * * |
|
| June 5, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on June 5, 2020 Registration No. |
|
| June 5, 2020 |
Amended and Restated Certificate of Incorporation of the registrant, as amended Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AKOUOS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Akouos, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That the name of this corpora |
|
| June 5, 2020 |
Subsidiaries of the registrant Exhibit 21.1 List of Subsidiaries Name Jurisdiction of Incorporation Akouos Securities Corporation Massachusetts |
|
| June 5, 2020 |
Form of Restricted Stock Agreement under 2020 Stock Plan Exhibit 10.9 Akouos, Inc. RESTRICTED STOCK AGREEMENT Akouos, Inc. (the “Company”) hereby grants the following award of restricted stock pursuant to its 2020 Stock Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number of shares of the restricted common stock, $0.0001 par value per share (the “Common Stock”) a |
|
| June 5, 2020 |
Form of Stock Option Agreement (Installment Exercise) under 2016 Stock Plan Exhibit 10.4 AKOUOS, INC. 2016 STOCK PLAN NOTICE OF STOCK OPTION GRANT (INSTALLMENT EXERCISE) The Optionee has been granted the following option to purchase shares of the Common Stock of Akouos, Inc.: Name of Optionee: «Name» Total Number of Shares: «TotalShares» Type of Option: «ISO» Incentive Stock Option (ISO) «NSO» Nonstatutory Stock Option (NSO) Exercise Price per Share: $«PricePerShare» Date |
|
| May 15, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As confidentially submitted to the Securities and Exchange Commission on May 15, 2020, as Amendment No. |
|
| April 27, 2020 |
Rosemary G. Reilly +1 617 526 6633 (t) +1 617 526 5000 (f) [email protected] April 27, 2020 By Electronic Submission Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Chris Edwards Re: Akouos, Inc. Draft Registration Statement on Form S-1 Filed March 24, 2020 CIK No. 0001722271 Ladies and Gentlemen: On behalf of Akouo |
|
| April 27, 2020 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on April 27, 2020, as Amendment No. |
|
| March 24, 2020 |
Double asterisks denote omissions. Exhibit 10.16 Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. EXECUTION VERSION AKOUOS, INC. [**] October 27, 2017 Massachusetts Eye and Ear Infirmary John Fernandez, President and CEO 243 Charles St. Boston, MA 02114 The Schepens |
|
| March 24, 2020 |
AKOUOS, INC. 2016 STOCK PLAN NOTICE OF STOCK OPTION GRANT (FULLY VESTED) EX-10.3 7 filename7.htm Exhibit 10.3 AKOUOS, INC. 2016 STOCK PLAN NOTICE OF STOCK OPTION GRANT (FULLY VESTED) The Optionee has been granted the following option to purchase shares of the Common Stock of Akouos, Inc.: Name of Optionee: «Name» Total Number of Shares: «TotalShares» Type of Option: «ISO» Incentive Stock Option (ISO) «NSO» Nonstatutory Stock Option (NSO) Exercise Price per Share: $«Pri |
|
| March 24, 2020 |
Exhibit 21.1 List of Subsidiaries Name Jurisdiction of Incorporation Akouos Securities Corporation Massachusetts |
|
| March 24, 2020 |
AKOUOS, INC. 2016 STOCK PLAN NOTICE OF STOCK OPTION GRANT (INSTALLMENT EXERCISE) Exhibit 10.4 AKOUOS, INC. 2016 STOCK PLAN NOTICE OF STOCK OPTION GRANT (INSTALLMENT EXERCISE) The Optionee has been granted the following option to purchase shares of the Common Stock of Akouos, Inc.: Name of Optionee: «Name» Total Number of Shares: «TotalShares» Type of Option: «ISO» Incentive Stock Option (ISO) «NSO» Nonstatutory Stock Option (NSO) Exercise Price per Share: $«PricePerShare» Date |
|
| March 24, 2020 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on March 24, 2020 Registration No. |
|
| March 24, 2020 |
SUBLICENSE AGREEMENT LONZA HOUSTON, INC. AKOUOS, INC. Exhibit 10.15 EXECUTION VERSION Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. SUBLICENSE AGREEMENT between LONZA HOUSTON, INC. and AKOUOS, INC. TABLE OF CONTENTS Page Article 1 - Definitions 1 Article 2 - Grant of Licenses, Reser |
|
| March 24, 2020 |
EX-3.1 2 filename2.htm Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AKOUOS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Akouos, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That t |
|
| March 24, 2020 |
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT EX-4.2 4 filename4.htm Exhibit 4.2 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 27th day of February, 2020, by and among Akouos, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, along with |
|
| March 24, 2020 |
AKOUOS, INC. 2016 STOCK PLAN NOTICE OF STOCK OPTION GRANT (EARLY EXERCISE) Exhibit 10.2 AKOUOS, INC. 2016 STOCK PLAN NOTICE OF STOCK OPTION GRANT (EARLY EXERCISE) The Optionee has been granted the following option to purchase shares of the Common Stock of Akouos, Inc.: Name of Optionee: «Name» Total Number of Shares: «TotalShares» Type of Option: «ISO» Incentive Stock Option (ISO) «NSO» Nonstatutory Stock Option (NSO) Exercise Price per Share: $«PricePerShare» Date of Gr |
|
| March 24, 2020 |
Exhibit 10.14 EXECUTION VERSION Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. LICENSE AGREEMENT between MASSACHUSETTS EYE AND EAR INFIRMARY AND THE SCHEPENS EYE RESEARCH INSTITUTE, INC. and AKOUOS, INC. TABLE OF CONTENTS Page Art |
|
| March 24, 2020 |
LEASE BETWEEN BOSTON HARBOR INDUSTRIAL DEVELOPMENT LLC AKOUOS, INC. ARTICLE 1 Reference Data Exhibit 10.12 LEASE BETWEEN BOSTON HARBOR INDUSTRIAL DEVELOPMENT LLC AND AKOUOS, INC. ARTICLE 1 Reference Data 1.1 Introduction: Each reference in this Lease to any of the following subjects shall be construed to incorporate the data stated for that subject in this Section 1.1. Lease Date: As of Dec. 28, 2018 Building: The building located at 645 Summer Street, Boston, MA, containing approximately |
|
| March 24, 2020 |
Exhibit 10.5 AKOUOS, INC. 2016 STOCK PLAN: SUMMARY OF STOCK PURCHASE The Purchaser is acquiring shares of the Common Stock of Akouos, Inc. on the following terms: Name of Purchaser: Total Number of Purchased Shares: Purchase Price per Share: Date of Purchase: Vesting Commencement Date: Vesting Schedule: By signing below, the Purchaser and the Company agree that the acquisition of the Purchased Sha |
|
| March 24, 2020 |
BYLAWS OF AKOUOS, INC. ARTICLE I OFFICES Exhibit 3.2 BYLAWS OF AKOUOS, INC. ARTICLE I OFFICES 1.1 Registered Office. The registered office shall be in the City of Wilmington, County of New Castle, State of Delaware. 1.2 Offices. The corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directors may from time to time determine or the business of the corporation may require. A |
|
| March 24, 2020 |
AKOUOS, INC. 2016 STOCK PLAN ADOPTED ON MARCH 1, 2017 Exhibit 10.1 AKOUOS, INC. 2016 STOCK PLAN ADOPTED ON MARCH 1, 2017 TABLE OF CONTENTS Page SECTION 1. ESTABLISHMENT AND PURPOSE 1 SECTION 2. ADMINISTRATION 1 (a) Committees of the Board of Directors 1 (b) Authority of the Board of Directors 1 SECTION 3. ELIGIBILITY 1 (a) General Rule 1 (b) Ten-Percent Stockholders 1 SECTION 4. STOCK SUBJECT TO PLAN 2 (a) Basic Limitation 2 (b) Additional Shares 2 S |
|
| March 24, 2020 |
AKOUOS, INC. 2016 STOCK PLAN: SUMMARY OF STOCK GRANT (FOR SERVICES) Exhibit 10.6 AKOUOS, INC. 2016 STOCK PLAN: SUMMARY OF STOCK GRANT (FOR SERVICES) The Transferee is acquiring shares of the Common Stock of Akouos, Inc. on the following terms: Name of Transferee: «Name» Total Number of Transferred Shares: «TotalShares» Date of Transfer: «DateTransfer» Vesting Commencement Date: «VestComDate» Vesting Schedule: The Forfeiture Condition shall lapse with respect to th |
